Recent improvement in long-term survival after a COPD hospitalisation

Thorax

Volumn 65, Issue 4, 2010, Pages 298-302

  Almagro, Pere ^a   Salvado M ^a   Garcia Vidal, C ^a   Rodriguez Carballeira, M ^a   Delgado, M ^a   Barreiro, B ^a   Heredia, J L ^a   Soriano, Joan B ^b  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b Fundacion Caubet CIMERA Illes Balears   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DYSPNEA; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RATING SCALE; SEX DIFFERENCE; SURVIVAL TIME;

EID: 77950873889     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.124818     Document Type: Article

References (35)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
3. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750 (Pubitemid 47321907)
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2008. http://www. goldcopd.org.
5. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009;136:376-380
6. Sin DD, Man SF. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:624-629 (Pubitemid 43782909)
7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789 (Pubitemid 46294610)
8. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554
9. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
10. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555 (Pubitemid 351650535)
11. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest 2002;121:1441-1448
12. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-467
13. Celli BR, MacNee W. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946
14. Peces-Barba G, Barberà JA, Agustí A, et al. Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT). Arch Bronconeumol 2008;44:271-281
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
16. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919
17. Seikh JI, Yesavage JA. Geriatric depression scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986;6:165-173
18. Mortality Register of Catalonia. Serveis d'Informació i estudis. Direcció general de recursos sanitaris. Departament de salut (elaboración propia).
19. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800 (Pubitemid 28052790)
20. Verdecchia A, Guzzinatis S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45:1042-1066
21. Brrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-883.
22. Shafazand M, Schaufelberger M, Lappas G, et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish hospital discharge registry. Eur Heart J 2009;30:671-678
23. Janda S, Park K, Fitzgerald JM, et al. Statins in COPD: a systematic review. Chest 2009;136:734-743
24. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-2560 (Pubitemid 43866389)
25. Luppi F, Franco F, Beghe B, et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008;5:848-856
26. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303
27. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931 (Pubitemid 41598207)
28. Domingo-Salvany A, Lamarca R, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;166:680-685
29. Celli B, Decramer M, Kesten S, et al. Mortality in the 4 year trial of tiotropium (UPLIFT) in patients with COPD. Am J Respir Crit Care Med 2009;180:948-955
30. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005;14:1899-1907 (Pubitemid 41161198)
31. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005;60:1025-1030 (Pubitemid 41705471)
32. McWilliams JM, Meara E, Zaslavsky AM, et al. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med 2009;21;150-215
33. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613 (Pubitemid 30329036)
34. Garcia-Aymerich J, Barreiro E, Farrero E, et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000;16:1037-1042 (Pubitemid 32148114)
35. Celli BR. Update on the management of COPD. Chest 2008;133:14512-14562